keyword
MENU ▼
Read by QxMD icon Read
search

HBV DNA

keyword
https://www.readbyqxmd.com/read/28525625/characteristics-of-us-born-versus-foreign-born-americans-of-african-descent-with-chronic-hepatitis-b
#1
Mohamed A Hassan, W Ray Kim, Ruosha Li, Coleman I Smith, Michael W Fried, Richard K Sterling, Marc G Ghany, Abdus S Wahed, Lilia M Ganova-Raeva, Lewis R Roberts, Anna S F Lok
Hepatitis B virus (HBV) infection is more common in African Americans than in white Americans. We compared the epidemiologic, clinical, and virological characteristics of US-born African Americans (USAAs) to those of foreign-born African Americans (FBAAs) with chronic hepatitis B. The adult cohort study of the Hepatitis B Research Network enrolls patients with HBV infection from 21 clinical sites in the United States and Canada. A total of 237 (15%) of the adult participants with chronic HBV infection that were enrolled from January 20, 2011, to October 2, 2013, were of African descent, including 57 USAAs and 180 FBAAs (76%)...
May 19, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28522916/early-hepatitis-b-viral-dna-clearance-predicts-treatment-response-at-week-96
#2
Xiao-Yu Fu, De-Ming Tan, Cui-Mei Liu, Bin Gu, Li-Hua Hu, Zhong-Tian Peng, Bin Chen, Yuan-Lin Xie, Huan-Yu Gong, Xiao-Xuan Hu, Lian-Hui Yao, Xiao-Ping Xu, Zheng-Yuan Fu, Lang-Qiu He, Si-Hai Li, Yun-Zhu Long, De-Hui Li, Ji-Long Gu, Shi-Fang Peng
AIM: To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS: A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk...
April 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28521640/antibody-mediated-immunotherapy-against-chronic-hepatitis-b-virus-infection
#3
Ying Gao, Tian-Ying Zhang, Quan Yuan, Ning-Shao Xia
The currently available drugs to treat hepatitis B virus (HBV) infection include interferons and nucleos(t)ide analogues, which can only induce disease remission and are inefficient for the functional cure of patients with chronic HBV infection (CHB). Since high titers of circulating hepatitis B surface antigen (HBsAg) may be essential to exhaust the host anti-HBV immune response and they cannot be significantly reduced by current drugs, new antiviral strategies aiming to suppress serum hepatitis B surface antigen (HBsAg) could help restore virus-specific immune responses and promote the eradication of the virus...
May 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28521532/new-antivirals-for-the-treatment-of-chronic-hepatitis-b
#4
Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M Peña, Carmen de Mendoza
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered: New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription...
May 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28514279/impact-of-alemtuzumab-on-hiv-persistence-in-an-hiv-infected-individual-on-antiretroviral-therapy-with-sezary-syndrome
#5
Thomas Aagaard Rasmussen, James McMahon, J Judy Chang, Jori Symons, Michael Roche, Ashanti Dantanarayana, Afam Okoye, Bonnie Hiener, Sarah Palmer, Wen Shi Lee, Stephen Kent, Carrie Van Der Weyden, H Miles Prince, Paul U Cameron, Sharon R Lewin
OBJECTIVE: To study the effects of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy (ART) with Sezary syndrome, a rare malignancy of CD4+ T-cells DESIGN:: Case report. METHODS: Blood was collected 30 and 18 months prior to presentation with Sezary syndrome, at the time of presentation and during alemtuzumab. T-cell subsets in malignant (CD7-CD26-TCR-VBeta2+) and non-malignant cells were quantified by flow cytometry. HIV-DNA in total CD4+ T-cells, in sorted malignant and non-malignant CD4+ T-cells was quantified by PCR and clonal expansion of HIV-DNA assessed by full-length next-generation sequencing...
May 16, 2017: AIDS
https://www.readbyqxmd.com/read/28513915/impact-of-a-determinant-mutations-on-detection-of-hepatitis-b-surface-antigen-hbsag-in-hbv-strains-from-chinese-patients-with-occult-hepatitis-b
#6
Xiangyan Huang, Chenyun Ma, Qiang Zhang, Qingfen Shi, Tao Huang, Chao Liu, Jie Li, F Blaine Hollinger
This study was designed to detect mutations that occur within the "a" determinant in the S gene of the hepatitis B virus (HBV) in patients with occult hepatitis B (OHB), and to analyze the influence of these mutations on expression and reactivity of the hepatitis B surface antigen (HBsAg). Twenty-three certified OHB samples were compared to 32 HBsAg positive samples from patients with chronic hepatitis B. The median HBV DNA levels in the OHB group were significantly lower than those in the control group (p < 0...
May 17, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28513813/hepatitis-b-virus-reactivation-after-effective-sofosbuvir-and-ribavirin-treatment-in-a-patient-with-occult-hepatitis-b-virus-infection
#7
Silvia Odolini, Paola Lanza, Angiola Angiola, Serena Zaltron, Lucia Urbinati, Andrea Vavassori, Paola Nasta, Elena Festa, Franco Gargiulo, Anna Rodella, Arnaldo Caruso, Salvatore Casari, Francesco Castelli, Mauro Viganò
Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC...
May 17, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28512353/favorable-response-to-long-term-nucleos-t-ide-analogue-therapy-in-hbeag-positive-patients-with-high-serum-fucosyl-agalactosyl-igg
#8
Cheng-Hsun Ho, Hung-Wen Tsai, Chen-Yeh Lee, Li-Juan Huang, Rong-Nan Chien, I-Chin Wu, Yen-Cheng Chiu, Wen-Chun Liu, Pin-Nan Cheng, Ting-Tsung Chang, Shu-Hui Chen
Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients...
May 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28511283/a-different-inhibitor-is-required-for-overcoming-entecavir-resistance-a-comparison-of-four-rescue-therapies-in-a-retrospective-study
#9
Guosheng Yuan, Chengguang Hu, Yuchen Zhou, Junwei Liu, Huaping Huang, Yuan Li, Dinghua Yang, Fuyuan Zhou, Yong-Yuan Zhang, Yuanping Zhou
AIMS: Little clinical data are available regarding reestablishing the effective inhibition of entecavir (ETV)-resistant mutants. In this retrospective study, we aimed to compare the efficacies of four treatment regimens as rescue therapy for those chronic hepatitis B (CHB) patients with ETV resistance. METHODS: A total of 65 patients with ETV resistance were assigned either with tenofovir disoproxil fumarate (TDF) monotherapy (n=21), ETV (0.5 mg) plus adefovir (ADV) combination therapy (n=19), ETV (1...
May 16, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28504722/thyroid-hormone-protects-hepatocytes-from-hbx-induced-carcinogenesis-by-enhancing-mitochondrial-turnover
#10
H-C Chi, S-L Chen, S-L Lin, C-Y Tsai, W-Y Chuang, Y-H Lin, Y-H Huang, M-M Tsai, C-T Yeh, K-H Lin
Infection by hepatitis B virus (HBV) accounts for 50-80% of hepatocellular carcinoma (HCC) development worldwide, in which the HBV-encoded X protein (HBx) has critical role in the induction of carcinogenesis. Several studies have shown that thyroid hormone (TH) suppresses HCC development and protects hepatocytes from HBx-induced damage, thus it is of interest to examine whether TH can protect hepatocytes from HBx-induced carcinogenesis. By treating HBx- transgenic mice with or without TH, we confirmed the protective effects of TH on HBx-induced hepatocarcinogenesis, which was achieved via reduction of reactive oxygen species (ROS) inflicted DNA damage...
May 15, 2017: Oncogene
https://www.readbyqxmd.com/read/28504115/protocatechuic-acid-inhibits-hepatitis-b-virus-replication-by-activating-erk1-2-pathway-and-down-regulating-hnf4%C3%AE-and-hnf1%C3%AE-in-vitro
#11
Xiao-Qing Dai, Wen-Tao Cai, Xiao Wu, Yong Chen, Feng-Mei Han
AIMS: Protocatechuic acid (PCA) is a phenolic compound found in many antiviral Chinese herbal medicines. HNF4α and HNF1α, the members of hepatocyte nuclear factor (HNF) family, play an important regulatory role in the gene transcription of hepatitis B virus (HBV). Previous studies found that PCA inhibited HBV antigen secretion and HBV DNA replication in HepG2.2.15 cells, but its anti-HBV mechanism has not been fully understood. We aim to illustrate the anti-HBV mechanism of PCA. MATERIALS AND METHODS: MTT was used to estimate cytotoxicity...
May 12, 2017: Life Sciences
https://www.readbyqxmd.com/read/28500726/mutations-associated-with-drug-resistance-and-prevalence-of-vaccine-escape-mutations-in-patients-with-chronic-hepatitis-b-infection
#12
Maria Isabel Magalhães A Dos Santos, Sidelcina Pacheco Rugiere, Andreas Stocker, Maria Isabel Schinoni, Raymundo Paraná, Mitermayer G Reis, Luciano K Silva
BACKGROUND: The Brazilian public health system (SUS) has provided antiviral drugs for chronic hepatitis B treatment for over 10 years, but a system for monitoring for drug-related resistance mutations is not available. OBJECTIVES: Determine the presence of HBV mutations associated with resistance to nucleos(t)ide analogs among 81 patients with chronic HBV infection in Salvador - BA - Brazil. STUDY DESIGN: HBV-DNA was PCR amplified with primers deduced from the rt domain at the HBV P gene, the sequence extended 1032 bp (from amino acid 1 to 344 - rt domain)...
May 13, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28500636/immune-correlates-of-hepatitis-b-surface-antigen-spontaneous-seroconversion-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients
#13
Ashish Kumar Vyas, Barjesh Chander Sharma, Shiv Kumar Sarin, Nirupma Trehanpati
BACKGROUND: Hepatitis B surface antigen (HBsAg) seroconversion in HBeAg-ve chronic hepatitis B (CHB) infection is rare, possibly due to poor antigen processing and impaired humoral response. We investigated the role of dendritic cells (DCs), T follicular helper (TFH) cells and plasma B cells in seroconversion. METHODS: HBeAg-ve (n=135) CHB patients with raised ALT at baseline were followed-up. Patients undergoing HBsAg sero-conversion (Gr. I, n=11) were compared with non-converters with low (Gr...
May 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28500322/incidence-and-predictors-of-hbv-relapse-after-cessation-of-nucleoside-analogues-in-hbeag-negative-patients-with-hbsag%C3%A2-%C3%A2-%C3%A2-200%C3%A2-iu-ml
#14
Chih-Chien Yao, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Hung Wang, Chung-Mo Lee, Chien-Hung Chen
The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg ≤ 200 IU/mL, were treated with lamivudine (n = 34) and entecavir (n = 85). The 5-year rates of post-treatment virological relapse, clinical relapse, and HBsAg loss at 60 months were 39.4%, 27.6%, and 45...
May 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28499864/role-of-hepatitis-b-core-protein-in-hbv-transcription-and-recruitment-of-histone-acetyltransferases-to-cccdna-minichromosome
#15
Chun Kong Chong, Ching Yan Serene Cheng, Sin Yi Jasmine Tsoi, Fung-Yu Huang, Fen Liu, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Danny Ka-Ho Wong
The hepatitis B core protein (HBc) has been suggested to interact with covalently closed circular DNA (cccDNA) and regulate hepatitis B virus (HBV) transcription. However, direct evidence is lacking. We aimed to identify the specific HBc region(s) responsible for transcription regulation and its interaction with cccDNA. Seventeen mutants with mutations at the four arginine-rich clusters of the HBc carboxyl-terminal domain (CTD) were created. The effect of HBc mutations on the levels of HBV DNA, RNA, and hepatitis B surface antigen (HBsAg) were measured...
May 10, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28499070/higher-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-vs-chronic-hepatitis-c-after-achievement-of-virologic-response
#16
Gi-Ae Kim, Seungbong Han, Hyung-Don Kim, Jihyun An, Young-Suk Lim
It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analyzed data from patients with CHB treated with entecavir (n=2000) or CHC treated with peg-interferon and ribavirin (n=733) at a tertiary hospital from 2004 through 2011. Virological response was defined as serum HBV DNA <15 IU/mL at 1 year of treatment for CHB or the achievement of sustained virologic response for CHC...
May 12, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28497124/parv4-prevalence-phylogeny-immunology-and-coinfection-with-hiv-hbv-and-hcv-in-a-multicentre-african-cohort
#17
Colin P Sharp, William F Gregory, Louise Hattingh, Amna Malik, Emily Adland, Samantha Daniels, Anriette van Zyl, Jonathan M Carlson, Susan Wareing, Anthony Ogwu, Roger Shapiro, Lynn Riddell, Fabian Chen, Thumbi Ndung'u, Philip J R Goulder, Paul Klenerman, Peter Simmonds, Pieter Jooste, Philippa C Matthews
Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, seroprevalence is high in the general population, but little is known about the transmission routes or the prevalence of coinfection with blood-borne viruses, HBV, HCV and HIV.  Methods: To further explore the characteristics of PARV4 in this setting, with a particular focus on the prevalence and significance of coinfection, we screened a cohort of 695 individuals recruited from Durban and Kimberley (South Africa) and Gaborone (Botswana) for PARV4 IgG and DNA, as well as documenting HIV, HBV and HCV status...
April 7, 2017: Wellcome Open Research
https://www.readbyqxmd.com/read/28494793/real-time-pcr-assays-for-hepatitis-b-virus-dna-quantification-may-require-two-different-targets
#18
Chao Liu, Le Chang, Tingting Jia, Fei Guo, Lu Zhang, Huimin Ji, Junpeng Zhao, Lunan Wang
BACKGROUND: Quantification Hepatitis B virus (HBV) DNA plays a critical role in the management of chronic HBV infections. However, HBV is a DNA virus with high levels of genetic variation, and drug-resistant mutations have emerged with the use of antiviral drugs. If a mutation caused a sequence mismatched in the primer or probe of a commercial DNA quantification kit, this would lead to an underestimation of the viral load of the sample. The aim of this study was to determine whether commercial kits, which use only one pair of primers and a single probe, accurately quantify the HBV DNA levels and to develop an improved duplex real-time PCR assay...
May 12, 2017: Virology Journal
https://www.readbyqxmd.com/read/28494252/design-synthesis-and-primary-biological-evaluation-of-the-novel-2-pyridone-derivatives-as-potent-non-nucleoside-hbv-inhibitors
#19
Haiyong Jia, Yang Song, Ji Yu, Peng Zhan, Diwakar Rai, Xiaohong Liang, Chunhong Ma, Xinyong Liu
In continuation of our efforts toward the discovery of potent non-nucleoside hepatitis B virus (HBV) inhibitors with novel structures, we have employed bioisosterism and hybrid pharmacophore-based strategy to explore the chemically diverse space of bioactive compounds. Cytotoxicity, anti-HBV antigen secretion activities and anti-HBV DNA replication activity were assayed with cell counting kit-8 (CCK-8), enzyme linked immunosorbent assay (ELISA) and a real-time PCR, respectively. Some of the new compounds were able to inhibit the replication of HBV DNA activity in the low micromolar range...
April 24, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28493307/hepatitis-b-virus-screening-and-reactivation-and-management-of-patients-with-nasopharyngeal-carcinoma-a-large-scale-big-data-intelligence-platform-based-analysis-from-an-endemic-area
#20
Jia-Wei Lv, Yu-Pei Chen, Xiao-Dan Huang, Guan-Qun Zhou, Lei Chen, Wen-Fei Li, Ling-Long Tang, Yan-Ping Mao, Ying Guo, Rui-Hua Xu, Jun Ma, Ying Sun
BACKGROUND: Chemotherapy, target therapy, and immunotherapy are increasingly being used in the systematic treatment of nasopharyngeal carcinoma (NPC), during which the occurrence of hepatitis B virus (HBV) reactivation might increase. However, data regarding HBV screening and reactivation and the clinical management of NPC patients with HBV infections are lacking. This study was aimed at clarifying the risk of reactivation for NPC patients on different regimens while providing evidence concerning HBV screening and management in an endemic area...
May 10, 2017: Cancer
keyword
keyword
53389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"